ArticleFrontiers in oncology2022

The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China.

Qingxiao Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.